Open access · US-GOV
via ClinicalTrials.gov Clinical trial
Trial of Oxaloacetate in Alzheimer's Disease (TOAD)
Authors not listed
Russell Swerdlow · 2015
Abstract
The purpose of this study is to determine if oxaloacetate (OAA) is safe and tolerable at doses of up to 2 grams per day in people with Alzheimer's disease (AD).
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- ClinicalTrials.gov
- Canonical
- link ↗
- Fetched
- 2026-11-01 MST
Cite this
APA
Anonymous. (2015). Trial of Oxaloacetate in Alzheimer's Disease (TOAD). <em>Russell Swerdlow</em>. https://clinicaltrials.gov/study/NCT02593318
Vancouver
Anonymous. Trial of Oxaloacetate in Alzheimer's Disease (TOAD). Russell Swerdlow. 2015.
BibTeX
@misc{anon2015Trialo,
title = {Trial of Oxaloacetate in Alzheimer's Disease (TOAD)},
author = {Anonymous},
journal = {Russell Swerdlow},
year = {2015},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
H. Lundbeck A/S 2015
Open access · US-GOV
Interventional, Open-label, Multiple-immunization Extension Study on the Safety, Tolerability and Immunogenicity of Lu AF20513/Adjuvant in Patients With Alzheimer's Disease
Beijing Friendship Hospital 2015
Open access · US-GOV
Monetary Cost of Alzheimer's Disease in China: Study Protocol for a Cluster Randomized Observational Study
Florida Atlantic University 2007
Open access · US-GOV
Delaying the Progression of Driving Impairment in Individuals With Mild Alzheimer's Disease
Medivation, Inc. 2009
Open access · US-GOV
CONTACT: A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Six-Month Safety and Efficacy Study of Dimebon in Patients With Moderate-to-Severe Alzheimer's Disease
Progress in molecular biology and translational science 2017
Preprint · OA
Mitochondria, Cybrids, Aging, and Alzheimer's Disease
Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 2011
Open access · OA